Literature DB >> 7336466

Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo.

A M Brodie, W M Garrett, J R Hendrickson, C H Tsai-Morris, P A Marcotte, C H Robinson.   

Abstract

4-Hydroxy-4-androstene-3,17-dione (4-OHA) and 4-acetoxy-4-androstene-3,17-dione (4-AcA), in addition to being competitive inhibitors of aromatase, cause time-dependent, irreversible, loss of enzyme activity in both human placental and rat ovarian microsomes. In vivo, treatment of rats with 4-OHA also causes loss of ovarian aromatase activity. To test whether this loss of activity could have in vivo significance, rats with hormone-dependent, mammary tumors were treated with 4-OHA on alternate weeks. Tumor regression continued to occur during the weeks without treatment. These findings suggest that inactivation of aromatase is important in the mechanism of action of the compounds in vivo.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7336466     DOI: 10.1016/0039-128x(81)90087-8

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  25 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.

Authors:  Debashis Ghosh; Jessica Lo; Chinaza Egbuta
Journal:  J Med Chem       Date:  2016-01-19       Impact factor: 7.446

Review 3.  Aromatase inhibitors: past, present and future in breast cancer therapy.

Authors:  Udayan Dutta; Kartikeya Pant
Journal:  Med Oncol       Date:  2007-11-01       Impact factor: 3.064

Review 4.  Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.

Authors:  L R Wiseman; K L Goa
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

Review 5.  Aromatase inhibitors--mechanisms of steroidal inhibitors.

Authors:  R W Brueggemeier
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 6.  The role of aromasin in the hormonal therapy of breast cancer.

Authors:  Magdolna Dank
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

7.  Liquid chromatography-mass spectrometry (LC-MS) of steroid hormone metabolites and its applications.

Authors:  Trevor M Penning; Seon-Hwa Lee; Yi Jin; Alejandro Gutierrez; Ian A Blair
Journal:  J Steroid Biochem Mol Biol       Date:  2010-01-18       Impact factor: 4.292

Review 8.  Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.

Authors:  L R Wiseman; D McTavish
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 9.  Second generation aromatase inhibitor--4-hydroxyandrostenedione.

Authors:  M Dowsett; R C Coombes
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 10.  Aromatase and its inhibitors in breast cancer treatment--overview and perspective.

Authors:  A M Brodie; R J Santen
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.